Jochen K. Lennerz

Active 2007–2026

160
Papers
19,366
Citations
70
h-index
147
i10-index

Citations

Citations per year for Jochen K. Lennerz1994: 1 citations1996: 1 citations2000: 1 citations2007: 2 citations2008: 9 citations2009: 82 citations2010: 115 citations2011: 123 citations2012: 135 citations2013: 139 citations2014: 181 citations2015: 148 citations2016: 153 citations2017: 191 citations2018: 213 citations2019: 670 citations2020: 1,043 citations2021: 1,134 citations2022: 864 citations2023: 735 citations2024: 1,145 citations2025: 646 citations2026: 33 citations1995: no citations, so this year is not shown1997–1999: no citations, so these years are not shown2001–2006: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,118 citing papers, 26.6% of this breakdownChina: 1,256 citing papers, 10.7% of this breakdownGermany: 690 citing papers, 5.9% of this breakdownItaly: 657 citing papers, 5.6% of this breakdownUnited Kingdom: 652 citing papers, 5.6% of this breakdownFrance: 482 citing papers, 4.1% of this breakdownJapan: 468 citing papers, 4% of this breakdownCanada: 351 citing papers, 3% of this breakdownSpain: 318 citing papers, 2.7% of this breakdownNetherlands: 302 citing papers, 2.6% of this breakdownAustralia: 270 citing papers, 2.3% of this breakdownSwitzerland: 240 citing papers, 2.1% of this breakdown
0%26.6%Other 24.8%

Fields

  • Medicine54.4%
  • Biochemistry, Genetics and Molecular Biology25.6%
  • Immunology and Microbiology9%
  • Computer Science3.9%
  • Neuroscience2.8%
  • Engineering1.2%
  • Other3.1%

Topics

  • Lung Cancer Treatments and Mutations5.5%
  • Cancer Genomics and Diagnostics3.8%
  • Lung Cancer Research Studies2.3%
  • IL-33, ST2, and ILC Pathways2.3%
  • Immune Cell Function and Interaction2.1%
  • Cancer Immunotherapy and Biomarkers1.9%
  • Other82.1%

Coauthors

All papers

Open in search
  1. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2021 cited by 517

  2. Recruited macrophages elicit atrial fibrillation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Filip K. Świrski, George Tellides, George Tolis, Serguei Melnitchouk, David J. Milan, Patrick T. Ellinor, Kamila Naxerova, Matthias Nahrendorf - Science 2023 cited by 206

  3. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells

    Authors: , , , , , , , , , , , , , , , , , - Nature 2008 cited by 1,508

  4. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mari Mino–Kenudson, Jeffrey A. Engelman, Alice T. Shaw - Cancer Discovery 2016 cited by 1,144

  5. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nabeel Bardeesy, Andrew X. Zhu - Cancer Discovery 2016 cited by 545

  6. Harmonized cross-species cell atlases of trigeminal and dorsal root ganglia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Science Advances 2024 cited by 198

  7. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robin Kate Kelley, Alberto Bardelli, A. John Iafrate, William C. Hahn, Cyril H. Benes, David T. Ting, Hiroshi Hirai, Gad Getz, Dejan Juric, Andrew X. Zhu, Ryan B. Corcoran, Nabeel Bardeesy - Cancer Discovery 2019 cited by 371

  8. Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine

    Authors: , , , , , , , , , , , , - Neuron 2022 cited by 194

  9. Origins of lymphatic and distant metastases in human colorectal cancer

    Authors: , , , , , , , , , , , - Science 2017 cited by 489

  10. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 cited by 139

  11. Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - EBioMedicine 2023 cited by 103

  12. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 cited by 306

  13. Computational pathology in cancer diagnosis, prognosis, and prediction – present day and prospects

    Authors: , , , , , , , , , , - The Journal of Pathology 2023 cited by 74

  14. Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barbara Leggett, Vicki Whitehall, Neal I. Walker, Ian Brown, Mark Bettington, Reiko Nishihara, Charles S. Fuchs, Jochen K. Lennerz, Marios Giannakis, Jonathan A. Nowak, Shuji Ogino - Clinical Cancer Research 2021 cited by 94

  15. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 cited by 227

  16. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 cited by 139

  17. RoboCap: Robotic mucus-clearing capsule for enhanced drug delivery in the gastrointestinal tract

    Authors: , , , , , , , , , , , , , , - Science Robotics, Sci. Robotics 2022 cited by 117

  18. Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 cited by 445

  19. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 194

  20. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 143

  21. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Giancarlo Pruneri, Sandra Demaria, Sylvia Adams, Stuart J. Schnitt, Sunil R. Lakhani, Federico Rojo, Laura Comerma, Sunil Badve, Mehrnoush Khojasteh, W. Fraser Symmans, Christos Sotiriou, Paula I. González-Ericsson, Katherine L. Pogue–Geile, Rim S. Kim, David L. Rimm, Giuseppe Viale, Stephen M. Hewitt, John M. S. Bartlett, Frédérique Penault–Llorca, Shom Goel, Huang‐Chun Lien, Sibylle Loibl, Zuzana Kos, Sherene Loi, Matthew G. Hanna, Stefan Michiels, Marleen Kok, Torsten O. Nielsen, Alexander J. Lazar, Zsuzsanna Bagó-Horváth, Loes Kooreman, Jeroen van der Laak, Joel Saltz, Brandon D. Gallas, Uday Kurkure, Michael Barnes, Roberto Salgado, Lee Cooper, International Immuno-Oncology Biomarker Working Group, Aini Hyytiäinen, Akira I. Hida, Alastair M. Thompson, Alexis Lefevre, Allen M. Gown, Amy Lo, Anna Sapino, André L. Moreira, Andrea L. Richardson, Andrea Vingiani, Andrew M. Bellizzi, Andrew Tutt, Ángel Guerrero‐Zotano, Anita Grigoriadis, Anna Ehinger, Ana C. Garrido-Castro, Anne Vincent-Salomon, Anne‐Vibeke Lænkholm, Ashley Cimino‐Mathews, Ashok Srinivasan, Balázs Ács, Baljit Singh, Benjamin C. Calhoun, Benjamin Haibe-Kans, Benjamin Solomon, Bibhusal Thapa, Brad H. Nelson, Carlos Castaneda, Carmen Ballesteroes-Merino, Carmen Criscitiello, Carolien Boeckx and 158 more - npj Breast Cancer 2020 cited by 166

  22. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adam L. Cohen, Shivangi Vora, Michael V. Knopp, Ian F. Dunn, Priya Kumthekar, Jann N. Sarkaria, Susan M. Geyer, Xiomara W. Carrero, Maria Martinez‐Lage, Daniel P. Cahill, Paul D. Brown, Caterina Giannini, Sandro Santagata, Frederick G. Barker, Evanthia Galanis - Journal of Clinical Oncology 2022 cited by 105

  23. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity

    Authors: , , , , , , , , - Nature 2008 cited by 1,225

  24. Odontoblast TRPC5 channels signal cold pain in teeth

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Science Advances 2021 cited by 91